Biosimilars | Market Events and Forecast Landscape – Forecast Methodology and General Market Assumptions | 2023
In 2021, sales of branded biologics for oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology indications exceeded $130 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in these therapy areas and countries totaled approximately $15 billion. Throughout our 2021-2031 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.
